[ Price : $8.95]
A Phase 3 trial funded by Novo Nordisk showed that its Ozempic/Wegovy outperformed placebo in patients with steatohepatitis and fi...[ Price : $8.95]
Chemistry & Engineering News reports that reductions in CDER Division of Drug Information staff are affecting FDAs ability to main...[ Price : $8.95]
A self-described radical HHS policy now requires all new vaccines to be evaluated in placebo-controlled trials before theyre licen...[ Price : $8.95]
FDA extends by three months its review of a Cytokinetics NDA for aficamten for treating patients with obstructive hypertrophic car...[ Price : $8.95]
FDA approves a Satsuma Pharmaceuticals 505(b)(2) NDA for Atzumi (dihydroergotamine (DHE)) nasal powder for the acute treatment of ...[ Price : $8.95]
Reps. Alexandria Orcasio-Cortez and Nydia Velzquez ask HHS secretary Robert F. Kennedy, Jr., to reopen the FDA San Juan medical pr...[ Price : $8.95]
Immunic reports positive data from its Phase 2 CALLIPER trial of nuclear receptor related 1 activator vidofludimus calcium (IMU-83...[ Price : $8.95]
Gilead Sciences agrees to pay $202 million to resolve claims that the company offered and paid kickbacks (e.g., honoraria payments...